16.12.2018 • News

Clariant and Eastman in Solvent Marketing Pact

Clariant and Eastman in Solvent Marketing Pact (c) Clariant
Clariant and Eastman in Solvent Marketing Pact (c) Clariant

Swiss specialty chemicals producer Clariant has signed on to exclusively market US chemical producer Eastman’s Tamisolve NxG solvent to the global agriculture sector. The solvent, which Clariant will market under its own trade name of Genagen NBP, is used in plant growth regulators, biological control agents, herbicides, fungicides, and insecticides.

The two chemical groups said the collaboration will deliver “significant business benefits to both agrochemical formulators and end customers,” especially given the dearth of effective, low-toxicity crop protection solutions on the market.

In a plant protection market governed by rigid regulations and increasing demand on efficiency, crop protection players must develop innovative, efficient, and environmentally-friendlier solutions, Clariant said. Eastman’s water miscible dipolar aprotic solvent, touted as a safer alternative to commonly used dipolar aprotic solvents, is claimed to work well in a variety of applications.

By its own account, the Swiss group has made “massive strides” in the agrochemicals market in recent years. In addition to expanding its portfolio of crop solutions, in 2017 the company announced an investment in an R&D greenhouse that houses opportunities for real-world crop protection testing and advances in future solutions.

 “Clariant’s formulation know-how and extensive reach into the market will ensure the success of this innovative ingredient,” said Dave Watson, director Agricultural Chemical Intermediates at Eastman.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.